Adagene Inc.
ADAG
Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-huā¦ read more
Healthcare
Biotechnology
2 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$1.84
Price+2.22%
$0.04
1Y
Price
Market Cap
$69.377m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow MarginRevenue
$103.200k
-
1y CAGR-
3y CAGR-
5y CAGREarnings
-$55.440m
-
1y CAGR-
3y CAGR-
5y CAGREPS
-$1.55
-
1y CAGR-
3y CAGR-
5y CAGRBook Value
$37.912m
$66.518m
Assets$28.605m
Liabilities$6.850m
DebtDebt to Assets
10.3%
-0.1x
Debt to EBITDAFree Cash Flow
-$47.587m
-
1y CAGR-
3y CAGR-
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company